FB 102
Alternative Names: FB-102Latest Information Update: 29 Aug 2024
At a glance
- Originator Forte Biosciences
- Class Antibodies; Skin disorder therapies
- Mechanism of Action Interleukin-2 receptor beta subunit antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Graft-versus-host disease
- Preclinical Alopecia areata; Coeliac disease; Vitiligo